TRPT1: A Drug Target and Biomarker for tRNA Splicing (G83707)

Target Name: TRPT1

NCBI ID: G83707

TRPT1

TRPT1: A Drug Target and Biomarker for tRNA Splicing

Transcriptional regulation is a complex process that involves the translation of DNA sequences into functional RNA molecules. One of the critical steps in this process is splicing, which is the process of removing non-coding regions from the RNA molecule and retaining only the coding regions. The regulation of splicing is crucial for the production of diverse RNA molecules that carry out various functions in the cell. One of the key enzymes involved in splicing is tRNA splicing 2' phosphotransferase 1 (TRPT1), which is an essential enzyme for the accurate splicing of RNA molecules. In this article, we will discuss TRPT1 as a drug target and biomarker.

The Importance of TRPT1

TRPT1 is an enzyme that plays a critical role in splicing RNA molecules. It is one of the three enzymes involved in the process of tRNA splicing, which is the most abundant type of splicing in the cell. The other two enzymes are TRPT2 and TRPT3. TRPT1 is responsible for the transfer of the 2' phosphate group from the tRNA to the splicling machinery. This transfer is critical for the initiation of the splicing reaction.

TRPT1 is a 21-kDa protein that contains a catalytic domain and a 150 amino acid tail. It has a distinct N-terminal and C-terminal region that are involved in the 2' phosphate transfer. The N-terminal region has a putative N-methyltransferase domain (NMT), which is known to play a role in the regulation of splicing. The C-terminal region has a catalytic domain that is responsible for the transfer of the 2' phosphate group from the tRNA to the splicling machinery.

Drug Targeting TRPT1

TRPT1 has been identified as a potential drug target due to its involvement in splicing regulation. Many studies have shown that blocking TRPT1 can prevent the formation of functional RNA molecules, which can lead to a variety of cellular consequences, including the inhibition of gene expression, cell death, and other cellular processes.

One of the mechanisms by which TRPT1 is involved in splicing regulation is its role in the regulation of the 2' phosphate level. tRNA splicing requires the 2' phosphate group from the tRNA to initiate the splicing reaction. TRPT1 is responsible for transferring this 2' phosphate group to the splicing machinery, which is necessary for the initiation of the splicing reaction. Therefore, inhibiting TRPT1 can prevent the formation of functional RNA molecules.

Another mechanism by which TRPT1 is involved in splicing regulation is its role in the regulation of the splicing machinery. TRPT1 is involved in the regulation of the splicing machinery by interacting with the protein splicing factor 1 (SPF1). SPF1 is a protein that plays a critical role in the regulation of splicing by binding to specific regions of the DNA and recruiting TRPT1 to the splicing machinery. Therefore, inhibiting TRPT1 can prevent the recruitment of SPF1 to the splicing machinery, which can lead to the inhibition of splicing.

Biomarker Analysis

TRPT1 has been shown to be involved in various cellular processes, including cell growth, apoptosis, and gene expression. Therefore, it is a potential biomarker for various diseases. One of the potential applications of TR

Protein Name: TRNA Phosphotransferase 1

Functions: Catalyzes the last step of tRNA splicing, the transfer of the splice junction 2'-phosphate from ligated tRNA to NAD to produce ADP-ribose 1''-2'' cyclic phosphate

The "TRPT1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about TRPT1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets